Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and Cancer of Head

pyrazines has been researched along with Cancer of Head in 36 studies

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (33.33)29.6817
2010's17 (47.22)24.3611
2020's7 (19.44)2.80

Authors

AuthorsStudies
Adkins, D; Algazi, A; Betts, CB; Cohen, EEW; Coussens, LM; Goldschmidt, JH; Guarino, MJ; Jimeno, A; Maloney, L; Munugalavadla, V; Nadler, E; Nemunaitis, J; Patel, P; Tao, L; Taylor, MH1
Axelrod, MJ; Bekiranov, S; David, AP; Donaldson, L; Dougherty, MI; Frierson, HF; Gioeli, DG; Hubbard, MA; Jameson, MJ; Khalil, AA; Lehman, CE; McGarey, PO; Mendez, RE; Petricoin, EF; Schoeff, SS; Stelow, EB; Taniguchi, LE; Wulfkuhle, JD1
Della Manna, DL; Nikolaev, A; Xing, C; Yang, ES; Zeng, L1
Distel, L; Dobler, C; Fietkau, R; Hecht, M; Jost, T1
Amaladas, N; Chaudhary, R; Chung, CH; Conejo-Garcia, JR; Hall, GE; Hernandez-Prera, JC; Masannat, J; McCleary-Sharpe, KP; Slebos, RJC; Song, F; Tan, AC; Wang, X; Wu, W1
Arasaki, A; Kawabata-Iwakawa, R; Kina, S; Kinjo, T; Miyamoto, S; Sunakawa, H1
Bürkel, F; Distel, LV; Faulhaber, EM; Fietkau, R; Hecht, M; Jost, T; Scheper, J; Symank, J1
Jin, X; Li, XF; Wang, JY; Zhang, X1
Johnson, DE; Li, C2
Borst, G; Clayton, J; Collins, I; Federspiel, MJ; Garrett, M; Harrington, KJ; Karapanagiotou, EM; Khan, AA; Kyula, J; Mansfield, D; McLaughlin, M; Pencavel, T; Roulstone, V; Russell, SJ; Touchefeu, Y; Zaidi, SH1
Johnson, DE; Kirk, CJ; Zang, Y1
Ayaz, B; Bullenkamp, J; Kulms, D; Odell, E; Raulf, N; Tavassoli, M; Thavaraj, S; Walczak, H1
Beggs, RR; Cooper, TS; Weaver, AN; Yang, ES; Zeng, L1
Grandis, JR; Johnson, DE; Li, C; Li, R1
Allen, C; Arun, P; Chen, Z; Nottingham, L; Saigal, K; Van Waes, C1
Bagain, L; Chen, Z; Lee, TL; Malhotra, PS; Nottingham, L; Ricker, JL; Van Waes, C; Yeh, NT1
Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J1
Grandis, JR; Johnson, DE; Li, C; Li, R; Patel, NS; Zang, Y1
Grandis, JR; Johnson, DE; Leeman-Neill, RJ; Li, C; Man, DS; Sen, M; Zang, Y1
Aulino, J; Baumann, J; Burkey, B; Chung, CH; Cmelak, AJ; Gilbert, J; Hatakeyama, H; Muldowney, NJ; Murphy, BA; Netterville, J; Parker, J; Shyr, Y; Sinard, R; Slebos, RJ; Yarbrough, WG1
Chang, I; Chen, X; Guan, J; Han, D; Kim, J; Wang, CY1
Chang, I; Chen, Z; Kang, M; Song, J; Wang, CY1
Argiris, A; Axelrod, RS; Burtness, B; Deconti, RC; Forastiere, AA; Ghebremichael, M1
Ahsan, A; Arai, Y; Argiris, A; Chen, Z; Cooley-Zgela, T; Duffy, AG; Jang, M; Kannabiran, VR; Kim, SW; Kummar, S; Nyati, MK; Ramanand, SG; Rudy, SF; Simone, NL; Suksta, N; Van Waes, C; Wright, JJ; Yang, X1
Ahn, PH; Anne, PR; Axelrod, RS; Cognetti, D; Curran, WJ; Dicker, AP; Fogh, S; Kubicek, GJ; Machtay, M; Myers, TJ1
Chen, CC; Chen, KC; Chen, KF; Cheng, AL; Lin, YC1
Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C1
Ishiyama, T; Jinguu, A; Kikuchi, J; Matsumoto, H; Suzuki, T; Yamakawa, M1
Chan, ET; DeLancey, HM; Freilino, ML; Grandis, JR; Johnson, DE; Kirk, CJ; Li, C; Thomas, SM; Zang, Y1
Fribley, A; Wang, CY; Zeng, Q1
Adams, J; Camphausen, K; Chang, AA; Chen, Z; Conley, BA; Druzgal, CH; Elsayed, YA; Gius, D; Lebowitz, PF; Mitchell, JB; Morris, JC; Rudy, SF; Sausville, EA; Sunwoo, JB; Van Waes, C1
Brown, RE; Kennedy, TL; Law, A; Lun, M; Pellitteri, PK; Zhang, PL1
Cerniglia, GJ; Gupta, AK; Maity, A; Weber, CN1
Ara, G; Chen, Z; Duan, J; Friedman, J; Nottingham, L; Van Waes, C1
Ackermann, H; Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Strebhardt, K; Wagenblast, J1

Trials

7 trial(s) available for pyrazines and Cancer of Head

ArticleYear
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, Mar-01, Volume: 28, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Head and Neck Neoplasms; Humans; Programmed Cell Death 1 Receptor; Proteomics; Pyrazines; Squamous Cell Carcinoma of Head and Neck

2022
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Pyrazines; Recurrence; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome

2010
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
    Cancer, 2011, Aug-01, Volume: 117, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Recurrence; Survival Analysis

2011
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Cytokines; Disease Progression; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Radiotherapy, Intensity-Modulated; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transcription Factors; Treatment Outcome

2011
Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.
    International journal of radiation oncology, biology, physics, 2012, Jul-15, Volume: 83, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines; Radiotherapy Dosage; Therapeutics

2012
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Oral oncology, 2012, Volume: 48, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Head and Neck Neoplasms; In Vitro Techniques; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Experimental; Polymerase Chain Reaction; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Signal Transduction

2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
    Head & neck, 2013, Volume: 35, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2013

Other Studies

29 other study(ies) available for pyrazines and Cancer of Head

ArticleYear
Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.
    The Laryngoscope, 2020, Volume: 130, Issue:6

    Topics: Head and Neck Neoplasms; Humans; Imidazoles; Insulin-Like Growth Factor I; Mouth Neoplasms; Neoplasm Staging; Pyrazines; Pyrazoles; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Triazines; Tumor Cells, Cultured

2020
CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
    Molecular cancer therapeutics, 2020, Volume: 19, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Checkpoint Kinase 1; Checkpoint Kinase 2; Chemoradiotherapy; Cisplatin; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Pyrazines; Pyrazoles; Receptors, Notch; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020
Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells.
    Cells, 2020, 09-01, Volume: 9, Issue:9

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cellular Senescence; DNA Damage; Fibroblasts; Head and Neck Neoplasms; Humans; Isoxazoles; Male; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinolines; Radiation, Ionizing; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Triazoles

2020
Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.
    Molecular carcinogenesis, 2021, Volume: 60, Issue:2

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Head and Neck Neoplasms; Humans; Male; Mice, Inbred C57BL; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Survival Analysis; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays

2021
A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
    Journal of drug targeting, 2021, Volume: 29, Issue:10

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Drug Synergism; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Pyrazines; Pyridines; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Tongue Neoplasms; Wnt Signaling Pathway; Young Adult

2021
Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells.
    Genes, 2021, 06-17, Volume: 12, Issue:6

    Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cells, Cultured; DNA Repair; DNA-Activated Protein Kinase; Head and Neck Neoplasms; Humans; Isoxazoles; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinolines; Triazoles; X-Rays

2021
CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
    Biochemical and biophysical research communications, 2018, 02-19, Volume: 496, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Pyrazines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Treatment Outcome

2018
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
    Cell cycle (Georgetown, Tex.), 2013, Mar-15, Volume: 12, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Papillomavirus Infections; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Repressor Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Tumor Suppressor Protein p53; Ubiquitination

2013
Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013, Volume: 108, Issue:1

    Topics: Animals; Cell Line, Tumor; Checkpoint Kinase 1; Colorectal Neoplasms; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Isoquinolines; Measles virus; Mice; Oncolytic Virotherapy; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Radiation-Sensitizing Agents; Symporters; Virus Replication; Xenograft Model Antitumor Assays

2013
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
    Cancer biology & therapy, 2014, Volume: 15, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mitochondrial Proteins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Vorinostat

2014
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Cell death & disease, 2014, Oct-23, Volume: 5

    Topics: Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Head and Neck Neoplasms; HEK293 Cells; Humans; Oncogene Proteins, Viral; Papillomaviridae; Protein Stability; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein

2014
Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Checkpoint Kinase 1; Checkpoint Kinase 2; Chemoradiotherapy; Combined Modality Therapy; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Pyrazines; Pyrazoles; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays

2017
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Membrane Proteins; Mitochondrial Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Up-Regulation

2008
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-01, Volume: 14, Issue:13

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Nucleus; DNA; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Models, Biological; NF-kappa B; Phosphorylation; Pyrazines; Recurrence; Signal Transduction; Subcellular Fractions

2008
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:7

    Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Drug Synergism; Genes, Reporter; Head and Neck Neoplasms; Humans; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Transcription Factor AP-1; Ubiquitination; Xenograft Model Antitumor Assays

2008
Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.
    Oncology reports, 2008, Volume: 20, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dexamethasone; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines

2008
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Molecular pharmacology, 2009, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synergism; Head and Neck Neoplasms; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Sulfonamides

2009
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:8

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Up-Regulation

2009
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Xenograft Model Antitumor Assays

2010
Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling.
    PloS one, 2010, Jul-06, Volume: 5, Issue:7

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; beta Catenin; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Etoposide; Flow Cytometry; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Pyrazines; Signal Transduction; Stem Cells; Wnt Proteins

2010
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
    Cancer letters, 2012, Jan-01, Volume: 314, Issue:1

    Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Activation; Head and Neck Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Squamous Cell Carcinoma of Head and Neck

2012
[A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Doxorubicin; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melphalan; Middle Aged; Mitolactol; Mitomycins; Neuroectodermal Tumors, Primitive; Pyrazines; Salvage Therapy; Suicide; Tomography, X-Ray Computed

2012
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
    Autophagy, 2012, Volume: 8, Issue:12

    Topics: Activating Transcription Factor 4; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Head and Neck Neoplasms; Humans; Models, Biological; Oligopeptides; Proteasome Inhibitors; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Unfolded Protein Response

2012
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Molecular and cellular biology, 2004, Volume: 24, Issue:22

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Endoplasmic Reticulum; Gene Expression Profiling; Head and Neck Neoplasms; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Signal Transduction

2004
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
    International journal of radiation oncology, biology, physics, 2005, Dec-01, Volume: 63, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cytokines; Female; Gene Expression; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasm Recurrence, Local; NF-kappa B; Protease Inhibitors; Pyrazines; Stomatitis; Transcription Factor RelA

2005
Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Annals of clinical and laboratory science, 2005,Summer, Volume: 35, Issue:3

    Topics: Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; NF-kappa B; Pyrazines; RNA, Small Interfering; Transfection

2005
Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation.
    Cancer biology & therapy, 2007, Volume: 6, Issue:2

    Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Head and Neck Neoplasms; Humans; Pyrazines; Radiation Dosage; Radiation-Sensitizing Agents

2007
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:1

    Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; NF-kappa B p50 Subunit; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Small Interfering; Sulfonamides; Transcription Factor RelA; Xenograft Model Antitumor Assays

2007
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines; Taxoids

2008